These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29831)

  • 21. Platelet monoamine-oxidase activity in schizophrenia. Relation to genetic load of the illness and treatment with antipsychotic drugs.
    Kemali D; Maj M; Ariano MG; Salvati A
    Encephale; 1985; 11(1):31-4. PubMed ID: 2859981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet monoamine oxidase and serum dopamine-beta-hydroxylase activities in psychotic patients.
    Zizolfi S; Famiglietti LA; Del Vecchio M; Kemali D
    Acta Neurol (Napoli); 1979 Apr; 1(2):142-9. PubMed ID: 474224
    [No Abstract]   [Full Text] [Related]  

  • 23. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
    Leuner K; Müller WE
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The ratio of blood platelet monoamineoxidase to aldehyde reductase activity in paranoid schizophrenia (author's transl)].
    Landowski J; Wontrobski Z
    Psychiatr Pol; 1981; 15(2):133-7. PubMed ID: 7312994
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of relation between dopaminergic and gabaergic mechanisms in chick retina.
    Nistico G; De Sarro A; Urna G; Pujia A; Ientile R
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):29-39. PubMed ID: 6135247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms].
    Heinz A; Przuntek H; Winterer G; Pietzcker A
    Nervenarzt; 1995 Sep; 66(9):662-9. PubMed ID: 7477603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.
    Alexander M; Rothman RB; Baumann MH; Endres CJ; Brasić JR; Wong DF
    Synapse; 2005 May; 56(2):94-9. PubMed ID: 15729739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
    Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
    Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcoholics with reduced dopamine D2 receptor function possess normal platelet monoamine oxidase activity.
    Balldin J; Berggren U; Lindstedt G; Oreland L
    Alcohol Alcohol; 1994 Nov; 29(6):659-61. PubMed ID: 7695780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA; Awouters FH
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosis pathways converge via D2high dopamine receptors.
    Seeman P; Schwarz J; Chen JF; Szechtman H; Perreault M; McKnight GS; Roder JC; Quirion R; Boksa P; Srivastava LK; Yanai K; Weinshenker D; Sumiyoshi T
    Synapse; 2006 Sep; 60(4):319-46. PubMed ID: 16786561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biological approaches to acute psychoses].
    Poirier MF
    Encephale; 1999 Nov; 25 Spec No 3():33-9. PubMed ID: 10598292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 35. A critique of the dopamine hypothesis of schizophrenia and psychosis.
    Moncrieff J
    Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of the dopaminergic system in the mechanism of action of psychotropic drugs].
    Valchár M
    Cesk Fysiol; 1980; 29(1):1-32. PubMed ID: 6101996
    [No Abstract]   [Full Text] [Related]  

  • 38. Schizophrenia: dopamine beta-hydroxylase activity and treatment response.
    Sternberg DE; VanKammen DP; Lerner P; Bunney WE
    Science; 1982 Jun; 216(4553):1423-5. PubMed ID: 6124036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical processes in schizophrenia: an update.
    Bowers MB
    Schizophr Bull; 1980; 6(3):393-403. PubMed ID: 6996079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma.
    Youdim MB; Aronson JK; Blau K; Green AR; Grahame-Smith DG
    Psychol Med; 1979 May; 9(2):377-82. PubMed ID: 472083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.